antibody_engineering

Antibody immunotherapy is transforming cancer care. Biointron explains how antibodies complement traditional treatments to improve patient outcomes.

Engineering CDR loops boosts binding strength. Biointron outlines strategies to optimize CDRs for developing potent therapeutic antibodies.

Somatic hypermutation drives high-affinity antibodies. Biointron explains its role in B cell evolution and therapeutic antibody optimization.

Fully human and humanized antibodies reduce immunogenicity. Biointron highlights their advantages in creating safer, more effective therapeutics.

AbDrop™ isolates diverse, high-affinity antibodies rapidly. Biointron shows how this platform transforms discovery with speed, scale, and precision.

Pharmacokinetics defines antibody behavior in the body. Biointron explains ADME principles and their role in designing effective antibody drugs.

AbDrop™ and HUGO-Ab™ accelerate discovery. Biointron demonstrates how these platforms cut timelines by delivering diverse, high-affinity antibodies faster.

Chimeric antibodies marked a milestone in drug development. Biointron reviews their creation and impact as a foundation for today’s therapeutic antibodies.

Heavy and light chain pairing ensures antigen recognition. Biointron explains its importance in antibody structure, function, and therapeutic application.

VHH libraries provide diverse nanobody options. Biointron builds and screens libraries to identify stable, high-affinity binders for diagnostics and therapeutics.

Bispecific antibodies target two antigens simultaneously. Biointron explains their advantages and role in advancing next-generation therapeutic development.

Effector functions drive antibody impact. Biointron reviews ADCC, CDC, and other mechanisms that enable antibodies to protect health and guide new therapies.

ADCs combine antibody targeting with potent drugs. Biointron outlines unique properties, advantages, and applications that make ADCs vital therapeutic tools.

ADC biosimilars and biobetters differ in design and benefit. Biointron explains distinctions and how innovation improves safety, efficacy, and patient outcomes.

VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!